The analysis uncovered (1) proteomic subtypes that integrate tumor-immune and stromal components, linking these subtypes to clinical and histopathological features, (2) classifications specifically for BRAF V600-mutated metastases, and (3) subgroups defined by the TME. The gene discussed is BRAF; the disease is neoplasm.